Leading into Budget week in Canberra this week, was a journey in planning, months in advance by member based groups, to advocate for new policy and funding changes in the Australian Health System.
Some paths are taken because of new crises to be addressed in the workforce, others in considering new models of care to treat patients, or simply to get new medications onto the PBS.
Australian Health Journal met with a number of industry heads after the budget on their journeys so far in lobbying for change, their achievements, some of the disappointments and their thoughts on the road ahead, with an election round the corner.
Skip ahead:
00:35 Tegan Carrison, Executive Director Australian Association of Psychologists Inc (AAPi)
03:12 John Bruning, CEO Australasian College of Paramedicine (ACP)
09:09 Paul Sadler, CEO Aged and Community Services Australia (ACSA)
12:06 Karen Booth, President Australian Primary Health Care Association (APNA)
19:45 Jo Armstrong, CEO Cystic Fibrosis Australia
23:25 Elizabeth de Somer, CEO Medicines Australia
-
New clinical research entity first to operate across both Australia and New Zealand
Over the past 30 years, 18,000 clinical trials that have been registered in Australia, with the sector contributing $1.4 billion to Australia’s economy annually. Trials are a critical aspect of evidence-based medicine, and are essential for testing how new treatments, tests and vaccines will work. In New Zealand they contribute $146 million to the New Zealand economy.
To capitalise on this unique position and growth, a coordinated multi-site clinical research operation was missing, until now.
-
Maximising benefits, minimising harms in population health screening
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
-
Nuclear medicine funding a win for men with prostate cancer
Australian men with higher risk prostate cancer now have access to a nuclear medicine scan to help detect and treat metastatic disease, after it was listed on the Medical Benefits Schedule (MBS) from 1st July 2022.
In 2021 over 18,000 Australian men were diagnosed with prostate cancer, resulting in over 3,000 lives being lost – and making prostate cancer Australia’s second most common cause of cancer death in men.
Australian Health Journal spoke with AANMS President Associate Professor Sze Ting Lee and Dr Geoff Schembri on the MBS listing and the efforts to get it listed.
